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Objective: To motivate the role for preference assessment
in women’s health and to report pilot data addressing the
performance of automated time-trade-off (TTO) valua-
tions of current health, which were developed to estimate
quality-adjusted life years (QALYs) in the women’s health
setting.
Methods: Values for current health relative to perfect
health and death were assessed using an annual time
trade-off (1-year horizon and sleep as the trading
metaphor), a lifetime time trade-off, and a visual analog
scale (VAS). All instruments were administered twice
within a 12- to 14-day window among a convenience
sample of 27 women.
Results: Valuation of health was similar for both time
trade-offs (mean of 0.95 for both), but was signiﬁcantly
lower for the VAS (mean of 0.84, Wilcoxon signed-rank
p-value < 0.001). Reliability using the intraclass correla-
tion coefﬁcient was 0.67 ± 0.09 and 0.75 ± 0.07 for 
the annual and lifetime time trade-offs, respectively, and
0.89 ± 0.03 for the VAS. Construct validity was sup-
ported by consistent trends in time-trade-off utilities
across tertiles of the Short Form 36 (SF-36) general health
subscale (trend test p-value < 0.001).
Conclusion: Automated time trade-offs for current health
provide a promising approach for use in women’s health
studies where impact on QALYs must be measured.
Natural areas of application include the economic evalu-
ation of preventive interventions in postmenopausal
women.
Keywords: cost-effectiveness, osteoporosis. quality-
adjusted life years, utility, women’s health. 
Address correspondence to: Anna N. A. Tosteson, ScD,
HB7505 Clinical Research, Dartmouth-Hitchcock Medical
Center, 1 Medical Center Drive, Lebanon, NH 03756. 
E-mail: anna.tosteson@dartmouth.edu
Volume 5 • Number 2 • 2002
V A L U E  I N  H E A L T H
Automated Current Health Time-Trade-Off Assessments in
Women’s Health
Anna N.A.Tosteson, ScD,1 Terry S. Kneeland, MPH,1 Robert F. Nease, PhD,2 Walton Sumner, MD2
1Center for the Evaluative Clinical Sciences, Department of Community and Family Medicine and Clinical Research Section,
Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire; 2Laboratory for Medical Decision Sciences
Washington University School of Medicine, St. Louis, Missouri 
ABSTRACT
Introduction
As more women consider long-term use of post-
menopausal pharmacological agents, such as
hormone replacement therapy (HRT) or selective
estrogen receptor modulators (SERMs) to prevent
osteoporosis and other diseases, it will become
increasingly important to understand the effects 
of these drugs on health-related quality of life. To
assess the economic value of such interventions
using quality-adjusted life years (QALYs) as the
health end point of interest, quantitative estimates
reﬂecting how women value their health are
required. These values, which are sometimes
referred to as utilities, are scaled from 0 (death or
worst imaginable health state) to 1 (perfect health
or best imaginable health state). When estimating
QALYs, each year of life is weighed according to its
quantitative value estimate or utility. Von Neumann
and Morgenstern [1] described the axiomatic basis
for utility assessment in the 1940s. Since then a
number of approaches to assessing values for health
states have been developed, including the time-
trade-off (TTO) technique described by Torrance 
et al. [2].
In contrast to health-status instruments such as
the Women’s Health Questionnaire [3], the purpose
of health valuation is to measure how women feel
about their health rather than to characterize their
particular functional health state. In the conceptual
model of patient outcomes described by Wilson and
Cleary [4], values and preferences are noted as inﬂu-
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encing both general health perceptions and overall
quality of life. Valuations of current (or global)
health aim to measure each individual’s preferences
for her overall health state [5]. Thus, two women
in identical health states as measured by a health-
status instrument such as the Short Form 36 (SF-
36) [6] who value their health differently would
have different utilities for current health.
The importance of such valuations in the eco-
nomic evaluation of interventions in women’s
health is nicely exempliﬁed by the ﬁndings of the
ﬁrst study to address the cost-effectiveness of 
estrogen replacement therapy in postmenopausal
women. Weinstein [7] showed that the long-term
beneﬁts of HRT could be outweighed among
asymptomatic women if they felt that HRT side
effects reduced quality of life by 2 to 3 days per year.
Despite the impact of such side effects on the results
of economic evaluations in women’s health, very
few data reﬂecting their affect on overall health 
valuation (i.e., QALYs) are available.
Feeny and Torrance [8] have described the role
for utility assessment as an adjunct to usual end
points in clinical trials. However, the large resources
required for deploying highly trained interviewers
at multiple sites are barrier to widespread imple-
mentation of such measures. Automated preference-
assessment tools such as U-Titer [9] and IMPACT
[10] facilitate consistent utility elicitation without 
a trained interviewer and thereby provide one solu-
tion to this problem [11,12].
Another approach to incorporating health-state
valuation in clinical trials is to use self-administered
preference classiﬁcation systems, such as the Health
Utilities Index (HUI) [8,13–15], EQ-5D [16–18], or
SF-6D [19]. A primary advantage of such instru-
ments is that they provide health-state valuations
based on societal preferences, which are most
appropriate for cost-effectiveness evaluation [20].
For diseases such as osteoporosis, which have a
large impact on physical function, preference clas-
siﬁcation systems may be sufﬁcient for characteriz-
ing health valuation. This conjecture is supported
by a cross-sectional study of women with fracture
where HUI provided similar health-state valuations
compared with directly assessed TTO values for
current health [21]. However, a primary disadvan-
tage of generic preference classiﬁcation systems is
that they may not be sensitive enough to character-
ize the inﬂuence of menopause and other factors 
on women’s health (e.g., the inﬂuence of vasomotor
symptoms on health valuation). This is of particu-
lar concern in the prevention trial setting where it
is essential to account for the inﬂuence of treatment
side effects on health valuation. Given this uncer-
tainty, preference classiﬁcation systems should be
considered as an adjunct rather than a replacement
for direct utility assessment.
As one step toward the economic evaluation 
of women’s health interventions, we developed an
automated computer-based interview to assess
current health valuation using two TTO techniques.
Both an annual TTO, appropriate for valuing
overall health or transient health problems, and 
a more traditional lifetime TTO, appropriate for
valuing long-term or chronic health conditions,
were implemented. In this paper, pilot data address-
ing the reliability and validity of these two current
health assessments among women are reported.
Applications of these instruments in women’s health
studies are also reviewed.
Methods
Study Population
A convenience sample of women employed by Dart-
mouth College was recruited for participation in a
study to evaluate the reliability of instruments mea-
suring valuation of current health. The pilot study,
which was conducted in 1994, was preceded by 
an investigation into the understandability of study
instruments. A primary focus of this study was 
to assess the performance of an annual TTO for
current health for the purpose of evaluating the
effect of a pharmaceutical intervention on near-term
health. The study was designed with two interviews
to be completed within a 12- to 14-day interval. The
order of instrument administration in our study 
was designed to parallel planned clinical trial use of
automated utility assessments. At each interview,
women completed a practice TTO assessment, an
annual TTO for current health, a lifetime TTO for
current health, a rating scale instrument, and a
subset of SF-36 health-status questions as detailed
in the next section [6].
Study Instruments
All current health assessments were implemented
using the automated U-Titer utility assessment
instrument [9]. U-Titer is a hypercard application
implemented on a MacIntosh computer operating
system (MacOS), which facilitates the development
of customized utility interviews. The automated
format facilitates a consistent presentation of ques-
tions and enables detailed electronic data collection.
U-Titer has been implemented in many disease areas
including psoriasis, heart disease, and women’s
health [22–24].
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Time Trade-Offs for Current Health 
Two automated time-trade-off assessments for
current health were developed. One, which we refer
to as the annual time trade-off, used a 1-year time
horizon and sleep as a metaphor for trading time as
depicted in Figure 1. The sleep metaphor was intro-
duced when it became evident in the understand-
ability testing phase of our pilot study that women
found it difﬁcult to trade off time without a con-
crete metaphor. This phenomenon was also noted
by Buckingham and colleagues [25], who studied
performance of a daily TTO (sleep metaphor) 
and annual TTO (convalescence metaphor). While
Buckingham and colleagues [25] found the daily
TTO (sleep metaphor) to have the best correlation
with health and best completion rates, they reported
little difference between the overall performance of
the two approaches.
The annual TTO was preceded by a training
question that gave women experience in using U-
Titer to value blindness using a 1-year time horizon
with sleep as the metaphor for trading time. A
description of time “asleep” was provided that read
as follows: Time “asleep” (as if it never happened)
means that you would be completely asleep for the
period of time you see in Choice A. Everyone else
would be awake and their activities would continue
without you. You would miss a period of time in
your life by being asleep. It does not mean you
would be in a coma or be damaged in any way when
you wake up. But you would continue to grow older
during the time you are “asleep.” Think about how
much time you would be willing to sleep, rather
than live with the health problem in Choice B.
A second TTO, which we refer to as a lifetime
or classic time trade-off, used actuarial life-
expectancy as the time horizon and premature
death as a metaphor for trading time (Fig. 2). The
search algorithm for both TTOs (i.e., the point of
indifference between choices A and B) used a bisec-
tion routine. First, participants were offered a
choice between perfect health and current health.
Most participants choose perfect health and are
then offered a trade between death today (or sleep-
ing for 12 months in annual TTO) or current
health. The U-Titer screens in Figures 1 and 2 re-
present the ﬁrst three trade-off screens seen by the
majority of participants.
At the end of the retest interview an alternate
form of the annual TTO, which used a slightly dif-
ferent wording for Choice A, was given to all par-
ticipants. The modiﬁed Choice A trade screen was
phrased as: “Spend the next year in perfect health
but spend X months asleep (as if they never 
happened).”
Visual Analog Scale
A visual analog scale (VAS) using perfect health and
death as the anchors was implemented within U-
Titer as a ruler.
Annual Time Trade-off
Choose one:
Spend the next year
in perfect health
AND
spend no extra time asleep
Spend the next year 
in your current health
Choice A Choice B
Choice C
Too hard to choose
between A & B
Choose one:
Be asleep
for the next year
(as if the year never happened)
Spend the next year 
in your current health
 
Choice A Choice B
Choice C
Too hard to choose
  between A & B
Choose one:
If Choice C, utility for current health= (12-6)/12 = 0.50
Spend the next 6 months
in perfect health
BUT
spend 6 months asleep
(as if they never happened)
Spend the next year  
in your current health
Choice A* Choice B
Choice C
Too hard to choose
between A & B
Figure1 Automated annual time trade-off as implemented in U-
Titer using a bisection search algorithm.A) First trade screen.Women
choosing A proceed to next panel. B) Second trade screen for women
choosing A in previous panel. Women choosing B proceed to next
panel. C) Third trade screen form women choosing B in previous
panel.
*The alternate version of Choice A is phrased as “Spend the next year 
in perfect health BUT spend 6 months asleep (as if they never happened).”
C
B
A
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Health Status
Following the health valuations, health status was
measured using a subset of the SF-36 question-
naire [6]. Items were selected such that the general
health and vitality domains of SF-36 could be 
computed.
Debrieﬁng
A trained interviewer debriefed women at the con-
clusion of the retest visit. The purpose of the
debrieﬁng was to assess whether women’s interpre-
tations of the annual TTO assessment were consis-
tent with the intended task.
Statistical Methods
Summary statistics were used to characterize the
study population. Wilcoxon signed-rank tests were
used to compare health valuations between instru-
ments at time 1. Paired t-tests were used to assess
differences between health values measured at the
two time points and between the two versions of
the annual TTO administered at retest. Test-retest
reliability of current health valuations and the
general health and vitality SF-36 subscales were
estimated using intraclass correlation coefﬁcients.
Box plots were used to describe variability in utili-
ties across tertiles of the SF-36 general-health sub-
scale. A nonparametric trend test was used to
evaluate trends in utilities across SF-36 general-
health tertiles [26]. Spearman rank correlations
between tertiles of general health and health-state
values were also estimated.
Results
Following the understandability testing phase, a
total of 27 women completed test and retest inter-
views within a 12- to 14-day interval. Women
ranged in age from 25 to 63 years of age. All were
employed and reported primarily excellent or very
good health as indicated in Table 1.
Valuations for current health were similar for
both trade-off assessments but signiﬁcantly lower
for the VAS (Wilcoxon signed rank test, p < .001)
(Table 2). Health-state values ranged from 0.5 to
1.0 with the annual TTO, from 0.68 to 1.0 with the
lifetime TTO, and from 0.49 to 0.99 with the VAS.
Among the 27 women studied, there were 15
unique health values obtained using the annual
TTO, 23 using the lifetime TTO, and 21 using the
VAS. Current health values of 1.0 were observed 
for both TTO instruments (6/27 [22%] for annual
Lifetime Time Trade-off
Choose one:
Live in perfect health
for 32 years
then die
(give up no time)
Live in your current health
for 32 years
then die
(give up no time) 
Too hard to choose
between A & B
Choice A Choice B
Choice C
Choose one:
Die today
(give up 32 years)
Live in your current health
for 32 years
then die
(give up no time) 
Too hard to choose
between A & B
Choice A Choice B
Choice C
Choose one:
If Choice C, utility for current health= (32-16)/32 = 0.50
Live in perfect health
for 16 years
then die
(give up 16 years)
Live in your current health
for 32 years
then die
(give up no time) 
Too hard to choose
between A & B
Choice A Choice B
Choice C
Figure 2 Automated lifetime time trade-off as implemented in U-
Titer using a bisection search algorithm shown for a participant with
32 years of remaining life expectancy. A) First trade screen.Women
choosing A proceed to next panel. B) Second trade screen for women
choosing A in previous panel. Women choosing B proceed to next
panel. C) Third trade screen form women chossing B in previous
panel.
Table 1 Summary of study participant characteristics
Characteristic Mean ± SD
Age 42 ± 8
Days between 13 ± 0.5
SF-36 general health subscale 71.8 ± 15.8
SF-36 vitality subscale 64.1 ± 11.9
Health rating (%)
Excellent 15
Very good 70
Good 11
Fair/poor 4
A
B
C
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TTO, and 4/27 for lifetime TTO), but not for the
VAS. Three women (9%) would not give up any
time in exchange for perfect health in either TTO.
At the debrieﬁng, the majority of women (20/27,
75%) were found to fully understand the annual
TTO task.
There were no signiﬁcant changes in mean values
from time 1 to time 2 (Table 2) or in the two 
versions of the annual TTO at retest. Reliability for
the annual TTO was 0.67 ± 0.09 (intraclass corre-
lation coefﬁcient ± standard deviation) and was
0.75 ± 0.07 for the lifetime TTO (Table 2). Test-
retest reliability for the rating scale was 0.89 ± 0.03.
Reliability for the general health and vitality sub-
scales of SF-36 were 0.90 ± 0.04 and 0.75 ± 0.09,
respectively.
There was a consistent tracking of values across
tertiles of the SF-36 general health subscale (Fig. 3)
with a signiﬁcant trend toward higher valuations
for better general health (trend test, p < .001).
Spearman rank correlations between general health
tertiles and health valuations, which were all sig-
niﬁcant, were 0.64, 0.41, and 0.53 for the annual
TTO, lifetime TTO, and VAS, respectively.
Discussion
When assessing the economic value of women’s
health interventions, it is desirable to measure their
impact on QALYs. Automated preference-
assessment tools [11,12] make it possible to collect
patient preference data in a consistent fashion in
multicenter studies. While others have reported on
the validity of automated instruments for measur-
ing health-state preferences [5,27], little has been
reported on their reliability. Most reliability studies
of TTO assessments have focused on the valuation
of health-state descriptions (e.g., EQ-5D health
states) rather than current health [28–30] and have
been interviewer administered. The reported 2-
week reliability for both current health TTO assess-
ments implemented in U-Titer (intraclass correla-
tion coefﬁcients of 0.67–0.75) was reasonable
relative to previous reports of classic interviewer-
administered TTO assessments (intraclass correla-
tion coefﬁcients of 0. 62–0.87 for retest periods of
one year to one week or less) [28]. In addition, using
the reliability of the general health and vitality sub-
scales as benchmarks for comparison, the annual
TTO had poorer reliability than either health status
subscale, while reliability for the lifetime TTO and
vitality subscale were similar. The current health
TTO values also tracked appropriately with general
health as measured by the SF-36 general health sub-
scale. These data suggest that automated TTOs
described here may be appropriate for use in
selected female populations.
In practice, choice of time horizon will be dic-
tated by the study objective and setting. It is impor-
tant that a time horizon that is meaningful to study
participants be used. One advantage of the annual
TTO over the lifetime assessment is that the inﬂu-
ence of time preference on utilities is minimized.
The annual TTO described here is most appropri-
ate when one wishes to characterize the potentially
transient effects of an intervention on QALYs. This
situation naturally arises in clinical trials of phar-
maceutical agents where potential drug side effects
may adversely or beneﬁcially affect QALYs. It is
Table 2 Summary of health valuations at time 1, differences
between times 1 and 2, and intraclass correlation coefﬁcients
for annual TTO (sleep metaphor), lifetime TTO (premature
death metaphor) and visual analog scale (prefect health and
death as anchors)
Annual TTO Lifetime TTO VAS
Mean ± SD at time 1 0.95 ± 0.11 0.95 ± 0.09 0.85 ± 0.12*
Mean change (time 1-
time 2) ± SD -0.02 ± 0.07 0.00 ± 0.06 -0.01 ± 0.05
Intraclass correlation 
coefﬁcient ± SD 0.67 ± 0.09 0.75 ± 0.07 0.89 ± 0.03
*Wilcoxon signed rank p < .001 when compared with annual or lifetime TTO
values.
Abbreviation:TTO, time trade-off;VAS, visual analog scale.
0
1
1 2 3
LifetimeAnnual Annual Annual
Low GH
(n = 10)
Mid GH
(n = 8)
High GH
  (n = 9)
Means:    0.883 0.903              0.977  0.942                ~1   0.995
LifetimeLifetime
Figure 3 Box and whisker plots showing values for current health
for lifetime and annual time trade-offs across tertiles of the SF-36
general health subscale. The boxes indicate the 25th and 75th per-
centiles (i.e., interquartile range-IQR) with the middle line indicating
the median value. Lines extending from the boxes (i.e., whiskers)
mark the upper and lower adjacent values, which are deﬁned as the
75th percentile +1.5*IQR and the 25th percentile -1.5*IQR. More
extreme values are individually plotted.
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important, however, to note that the sleep metaphor
may not be appropriate for use in assessing health-
state values among women experiencing acute
menopausal symptoms involving sleep distur-
bances. Investigators should consider collecting
data on perceived sleep needs and recent sleep expe-
rience when trade-offs involving the sleep metaphor
are implemented. Alternative TTO approaches to
valuing transient health states include use of an
annual TTO in which convalescence serves as the
trading metaphor [25], the use of chained TTOs
[31], or the evaluation of health paths [32,33].
Our pilot study had several important limitations
that must be addressed. First, our convenience
sample size of 27 women employed by Dartmouth
College was relatively small and participants likely
had higher socioeconomic status, educational
attainment levels, and health status than the general
population. As a result, our estimates of reliability
may represent a best-case scenario.
Second, because of our primary interest in 
estimating the reliability of the annual TTO, this
instrument was always presented following the
training task. Although women were not given a
ﬁnal preference score at the end of each assessment
task, we cannot rule out anchoring as a factor con-
tributing to higher reliability scores for the lifetime
TTO and VAS. While some have reported higher
reliability scores for visual analog scales [30], this
ﬁnding is not consistent across all studies [28].
Third, our evaluation of validity was limited by
the amount of additional health-status information
that we collected and by the number of health states
that were assessed. The latter precluded our use of
recently proposed methods for measuring the valid-
ity of utility assessments by considering the consis-
tency of rank orderings for multiple health states
across instruments [27,34]. However, when the
primary focus is on current-health valuation rather
than valuation of imagined health states (i.e.,
health-state descriptions), use of consistency rank-
ings may have limited applicability.
Several aspects of the TTO assessments that we
evaluated also deserve comment. First, although
development of the automated instruments was
motivated by applications in women’s health,
current health assessments are global measures 
of health preference and may ﬁnd application in 
a wide variety of disease areas. Our pilot data,
however, do not support use of these instruments in
the general female population, male populations, or
speciﬁc disease areas. Further investigation of the
reliability of these instruments is needed prior to
their use in other settings.
Second, by using death as a lower anchor in 
the lifetime TTO and VAS tasks, we did not allow
participants to rate their own health state as worse
than death [35]. Fortunately, this is unlikely to be
of practical importance when used to assess the
value of preventive health interventions. Differences
in scaling of utilities across studies could, however,
inﬂuence the comparability of cost-utility analyses
[36].
Finally, more recent versions of U-Titer allow
investigators to specify alternative search algo-
rithms. Because of the documented effect of the
search algorithm on the health-state values obtained
[37] we note that our pilot data apply only to 
the TTOs implemented using a bisection search
algorithm.
To date, the automated TTO assessments of
current health described here have been used in
several studies among women. The annual TTO
(using the modiﬁed choice A format) was used in 
a health-economic trial comparing raloxifene and
hormone replacement therapy for postmenopausal
osteoporosis prevention [11]. The annual trade-off
was implemented because the study’s objective was
to evaluate the effect of a pharmaceutical interven-
tion on the valuation of near-term health. This U-
Titer interview also included a valuation of side
effects, which are often transient, and required a
short rather than lifetime time horizon. In this
setting, use of the annual rather than lifetime
current health assessment had the added practical
advantage of requiring introduction to only one
trading metaphor. Although no longitudinal differ-
ences in health valuation between treatment groups
were noted [38], the detailed preference data col-
lected prospectively in this trial allowed for an
analysis of the impact of speciﬁc treatment-
emergent side effects on the incidence of low valua-
tion for current health [39].
The lifetime TTO for current health was used in
a continuing study whose objective is to identify
cost-effective approaches to osteoporosis preven-
tion and treatment in the elderly [21,24,40]. An
analysis of 382 women aged 50 to 96 years
addressed the impact of fractures on quality of life
using the classic TTO assessment and indicated that
women with hip and/or vertebral fractures would
give up 6 to 51% more of their remaining life years
to attain prefect health relative to women without
fracture [40]. In another analysis, which investi-
gated the impact of HRT on current health valua-
tion, current HRT users were found to have
signiﬁcantly higher values when compared with
never and past HRT users [24].
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In summary, when assessing the economic value
of preventive interventions on health, it is particu-
larly important that the effect of these interventions
on quality of life be considered. The automated
current-health TTO instruments described here
provide one approach for collecting preference data
when impact on QALYs must be addressed. Appli-
cations of these instruments in the women’s health
setting appear promising. We conclude that auto-
mated utility assessment instruments should be con-
sidered as one approach to characterizing the health
impact of women’s health interventions.
This research was supported in part by grant AG12262
from the National Institute on Aging.
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